title: Levofloxacin and Tobramycin for Severe Bacterial Keratouveitis.
abstract: OBJECTIVE
  To report on clinical features and outcome of severe bacterial keratouveitis.
  
  
  METHODS
  Twenty patients with severe bacterial keratouveitis treated with topical tobramycin and levofloxacin and oral levofloxacin were included. Main outcome measures were ulcers location, bacterial isolates, risk factors, visual prognosis.
  
  
  RESULTS
  Centrally located ulcer/abscess was present in 65% of patients. Contact lens (CL) wear was the most common risk factor (70%). Bacterial isolates were observed in 58% of patients, none resistant to tobramycin and levofloxacin. Pseudomonas aeruginosa was found in 47% of positive cases and in 64% of CL wearers. After therapy, the mean visual acuity improved significantly (p < 0.0001), particularly in contact lens wearers (p = 0.04) and in patients younger than 60 years old (p < 0.001).
  
  
  CONCLUSIONS
  Pseudomonas aeruginosa is the most frequent cause of bacterial keratouveitis and CL wear the most common risk factor. Topical tobramycin and levofloxacin and oral levofloxacin are effective in the treatment of bacterial keratouveitis.
authors.affiliation: a Ocular Immunovirology Service, Department of Ophthalmology, Sapienza University of Rome , Rome , Italy and.
authors.forename: Massimo
authors.initials: M
authors.lastname: Accorinti
authors.affiliation: a Ocular Immunovirology Service, Department of Ophthalmology, Sapienza University of Rome , Rome , Italy and.
authors.forename: Lorena
authors.initials: L
authors.lastname: Colao
authors.affiliation: a Ocular Immunovirology Service, Department of Ophthalmology, Sapienza University of Rome , Rome , Italy and.
authors.forename: Marta
authors.initials: M
authors.lastname: Gilardi
authors.affiliation: a Ocular Immunovirology Service, Department of Ophthalmology, Sapienza University of Rome , Rome , Italy and.
authors.forename: Michela
authors.initials: M
authors.lastname: Cecere
authors.affiliation: b Department of Infectious Disease , Sapienza University of Rome , Rome , Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Salotti
authors.affiliation: a Ocular Immunovirology Service, Department of Ophthalmology, Sapienza University of Rome , Rome , Italy and.|b Department of Infectious Disease , Sapienza University of Rome , Rome , Italy.
authors.forename: Francesca Romana
authors.initials: FR
authors.lastname: Pesci
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000302:isolation & purification; D003261:Contact Lenses / Q000009:adverse effects; D003320:Corneal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D064704:Levofloxacin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D012307:Risk Factors; D014031:Tobramycin / Q000627:therapeutic use*; D014606:Uveitis, Anterior / Q000188:drug therapy* / Q000382:microbiology; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D009883:Ophthalmic Solutions; D064704:Levofloxacin; D014031:Tobramycin
keywords: Antibiotic therapy; Pseudomonas aeruginosa; bacterial keratitis; contact lens; intraocular inflammation